| Secondary |
| Overdose |
50.0% |
| Product Used For Unknown Indication |
15.0% |
| Hypertension |
11.0% |
| Drug Use For Unknown Indication |
6.0% |
| Diabetes Mellitus |
4.0% |
| Agitated Depression |
2.0% |
| Dyslipidaemia |
2.0% |
| Prophylaxis Against Hiv Infection |
2.0% |
| Rheumatoid Arthritis |
2.0% |
| Vertigo |
2.0% |
| Anxiety |
1.0% |
| Depression |
1.0% |
| Gastritis Prophylaxis |
1.0% |
| Prophylaxis |
1.0% |
|
| Shock |
17.4% |
| Toxicity To Various Agents |
13.0% |
| Hypoxia |
8.7% |
| Transaminases Increased |
8.7% |
| Aphasia |
4.3% |
| Ataxia |
4.3% |
| Atrioventricular Block Complete |
4.3% |
| Cardiac Arrest |
4.3% |
| Cholelithiasis |
4.3% |
| Continuous Haemodiafiltration |
4.3% |
| Drug-induced Liver Injury |
4.3% |
| Hepatomegaly |
4.3% |
| Hypotension |
4.3% |
| Renal Failure Acute |
4.3% |
| Respiratory Tract Infection |
4.3% |
| Rhabdomyolysis |
4.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
22.1% |
| Hypertension |
18.1% |
| Drug Use For Unknown Indication |
15.6% |
| Diffuse Large B-cell Lymphoma |
7.5% |
| Diabetes Mellitus |
5.3% |
| Atrial Fibrillation |
4.2% |
| Prophylaxis |
3.9% |
| Rheumatoid Arthritis |
3.7% |
| Hepatic Neoplasm Malignant |
2.0% |
| Renal Transplant |
2.0% |
| Gastric Cancer |
1.9% |
| Blood Pressure |
1.7% |
| Cerebrovascular Accident Prophylaxis |
1.6% |
| Nephrogenic Anaemia |
1.6% |
| Pain |
1.6% |
| Premedication |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Blood Cholesterol Increased |
1.4% |
| Osteoporosis |
1.4% |
| Psoriasis |
1.4% |
|
| Guillain-barre Syndrome |
8.9% |
| Carotid Artery Stenosis |
7.9% |
| Peripheral Arterial Occlusive Disease |
7.9% |
| Tachycardia |
7.9% |
| Hypotension |
6.9% |
| Renal Failure |
5.9% |
| Breast Cancer |
5.0% |
| Renal Failure Acute |
5.0% |
| Rhabdomyolysis |
5.0% |
| Anaemia Haemolytic Autoimmune |
4.0% |
| Device Malfunction |
4.0% |
| Drug Interaction |
4.0% |
| Haemoglobin Decreased |
4.0% |
| Hypertension |
4.0% |
| Malaise |
4.0% |
| Osteonecrosis |
4.0% |
| Death |
3.0% |
| Dizziness |
3.0% |
| Hepatocellular Damage |
3.0% |
| Interstitial Lung Disease |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
66.7% |
| Prophylaxis Against Hiv Infection |
27.8% |
| Hiv Infection |
2.8% |
| Hypertension |
2.8% |
|
| Atrioventricular Block Complete |
33.3% |
| Hypotension |
33.3% |
| Atrioventricular Block |
11.1% |
| Drug Interaction |
11.1% |
| Tongue Oedema |
11.1% |
|
